SecBot SecBot
8-K ·Filed Nov 5, 2026

CTMX

CytomX Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 10h ago SEC0001193125-26-449787
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The earnings were in line with consensus, but the revenue decline and widening loss underscore the pre-revenue stage. The key catalyst is the Varseta-M data update in January 2027, which will inform registrational strategy. Monitor for any early data disclosures or FDA interactions before that date.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

CTMX drug pipeline →

Varseta-M

▲ Bullish Named in this 8-K
Impact
Phase
Phase 1
Time to market
If the Phase 1 update supports the registrational study planned for H1 2027, a potential FDA approval would likely be several years away, assuming successful pivotal trial execution. The Fast Track designation could accelerate timelines, but the drug is still in Phase 1 development.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 1 monotherapy data update in mCRC expected in January 2027 (roughly 2 months away). Positive data could support the planned registrational study start in H1 2027 and drive significant upside given the stock trades near cash value. Disappointing efficacy or safety signals could delay the pivotal program and pressure the stock toward its 52-week low of $2.11.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.19
T+0 close · Nov 5, 2026 · via day close
Latest settled
−6.85%
T+5 · $2.04 · next T+20 in 20d
Vs SPY
−9.44%
α at T+5
Latest observation
−8.27%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $2.19entry
  2. T+1 · 8d ago −9.59%α −11.96% · $1.98
  3. T+5 · 4d ago −6.85%α −9.44% · $2.04
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revenue decline reflects completion of the Astellas collaboration performance obligation. The company highlighted FDA Fast Track designation for Varseta-M and plans for a Phase 1 data update in January 2027, but the financial results show a pre-revenue clinical-stage biotech burning cash with no near-term product revenue.

Key Financial Metrics

Revenue
$1.7M
est $10.4M · -83.8% · -71.7% YoY

Key Facts

  • Q3 2026 revenue $1.7M vs $6.0M YoY, down 72%
  • Net loss $(20.0M) vs $(14.2M) loss YoY
  • Cash and investments $348.0M, runway into 2H 2028
  • FDA Fast Track designation for Varseta-M in relapsed/refractory mCRC granted in August 2026
  • Phase 1 monotherapy data update for Varseta-M expected January 2027
  • Phase 1 expansion cohorts initiated in gastric/GEJ, PDAC, and BTC

Financial Impact

Revenue fell 72% YoY to $1.7M; operating loss widened to $(23.5M) from $(15.8M); cash burn continues with $348M in cash

revenuenet incomeoperating expenses

Risk Factors

  • No approved products; entirely dependent on clinical success of Varseta-M and CX-801
  • Revenue decline reflects completion of collaboration agreements, no new revenue sources near term
  • Cash runway to 2H 2028 assumes no unexpected cost overruns or delays
  • Clinical trial risks: Varseta-M data may not support registrational study

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449787
Document: ctmx-20261105.htm0001193125-26-449787
Document: 0001193125-26-449787-index-headers.html0001193125-26-449787
Document: 0001193125-26-449787-index.html0001193125-26-449787
Document: 0001193125-26-449787.txt0001193125-26-449787
8-K Data (Synthetic)0001193125-26-449787

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026